Next Article in Journal
Genome Scale Transcriptomics of Baculovirus-Insect Interactions
Next Article in Special Issue
Phylogeographic Diversity of Pathogenic and Non-Pathogenic Hantaviruses in Slovenia
Previous Article in Journal
Roles of microRNAs in the Hepatitis B Virus Infection and Related Diseases
Previous Article in Special Issue
Increased Detection of Sin Nombre Hantavirus RNA in Antibody-Positive Deer Mice from Montana, USA: Evidence of Male Bias in RNA Viremia
Open AccessArticle

Ribavirin Protects Syrian Hamsters against Lethal Hantavirus Pulmonary Syndrome — After Intranasal Exposure to Andes Virus

1
Molecular Virology Branch, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21772, USA
2
Department of Microbiology and Immunology, Center for Predictive Medicine for Infectious Diseases and Biodefense, Louisville, KY 40202, USA
*
Authors to whom correspondence should be addressed.
Viruses 2013, 5(11), 2704-2720; https://doi.org/10.3390/v5112704
Received: 5 September 2013 / Revised: 23 October 2013 / Accepted: 31 October 2013 / Published: 8 November 2013
(This article belongs to the Special Issue Hantaviruses)
Andes virus, ANDV, harbored by wild rodents, causes the highly lethal hantavirus pulmonary syndrome (HPS) upon transmission to humans resulting in death in 30% to 50% of the cases. As there is no treatment for this disease, we systematically tested the efficacy of ribavirin in vitro and in an animal model. In vitro assays confirmed antiviral activity and determined that the most effective doses were 40 µg/mL and above. We tested three different concentrations of ribavirin for their capability to prevent HPS in the ANDV hamster model following an intranasal challenge. While the highest level of ribavirin (200 mg/kg) was toxic to the hamster, both the middle (100 mg/kg) and the lowest concentration (50 mg/kg) prevented HPS in hamsters without toxicity. Specifically, 8 of 8 hamsters survived intranasal challenge for both of those groups whereas 7 of 8 PBS control-treated animals developed lethal HPS. Further, we report that administration of ribavirin at 50 mg/kg/day starting on days 6, 8, 10, or 12 post-infection resulted in significant protection against HPS in all groups. Administration of ribavirin at 14 days post-infection also provided a significant level of protection against lethal HPS. These data provide in vivo evidence supporting the potential use of ribavirin as a post-exposure treatment to prevent HPS after exposure by the respiratory route. View Full-Text
Keywords: hantaviruses; ribavirin; hamster; prophylactic; post-exposure antiviral hantaviruses; ribavirin; hamster; prophylactic; post-exposure antiviral
Show Figures

Figure 1

MDPI and ACS Style

Ogg, M.; Jonsson, C.B.; Camp, J.V.; Hooper, J.W. Ribavirin Protects Syrian Hamsters against Lethal Hantavirus Pulmonary Syndrome — After Intranasal Exposure to Andes Virus. Viruses 2013, 5, 2704-2720.

Show more citation formats Show less citations formats

Article Access Map

1
Only visits after 24 November 2015 are recorded.
Back to TopTop